Literature DB >> 2899439

Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol.

J M McLenachan1, J T Wilson, H J Dargie.   

Abstract

Celiprolol (400 mg) and atenolol (100 mg) were given once a day to 16 patients with stable angina pectoris in a double blind placebo controlled crossover study. Celiprolol produced less suppression of heart rate both at rest and during exercise than atenolol. Both drugs were equally effective in reducing the frequency of angina and in delaying the onset of ischaemia during exercise. Radionuclide ventriculography showed that atenolol but not celiprolol lowered cardiac output at rest and during exercise. Thus the ancillary properties of celiprolol, including partial beta 2 agonist activity and direct vasodilating activity, have detectable effects on cardiac function that may be beneficial in patients with angina.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899439      PMCID: PMC1276876          DOI: 10.1136/hrt.59.6.685

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  8 in total

Review 1.  Beta-blocking drugs and myocardial function.

Authors:  S H Taylor
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  Celiprolol in angina pectoris: a controlled study.

Authors:  J Eff; J Godfrey; R Garutti; P Capone
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise.

Authors:  R R Nelson; F L Gobel; C R Jorgensen; K Wang; Y Wang; H L Taylor
Journal:  Circulation       Date:  1974-12       Impact factor: 29.690

4.  Effects of propranolol and isosorbide dinitrate on exercise performance and adrenergic acitivity in patients with angina pectoris.

Authors:  D J Battock; H Alvarez; C A Chidsey
Journal:  Circulation       Date:  1969-02       Impact factor: 29.690

5.  Mode of action of nitrglycerin in angina pectoris. Correlation between haemodynamic effects during exercise and prevention of pain.

Authors:  B F Robinson
Journal:  Br Heart J       Date:  1968-05

6.  Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.

Authors:  W M Kirby; J B De Maine; W S Serrill
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

7.  Celiprolol: pharmacokinetics and duration of pharmacodynamic activity.

Authors:  F S Caruso; H D Doshan; P H Hernandez; R Costello; W Applin; E S Neiss
Journal:  Br J Clin Pract Suppl       Date:  1985-06

Review 8.  Coronary insufficiency and beta-blockade.

Authors:  S H Taylor; B Silke
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

  8 in total
  7 in total

Review 1.  Required beta blocker profile in the elderly.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly.

Authors:  K D Lamon
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 4.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 5.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 6.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

7.  Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.

Authors:  G P Vyssoulis; M T Kouremetis; M A Valiouli; A P Michaelides; P K Toutouzas
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.